MakatiMed Partners with Top US Hospital to Advance Cancer Care

    MakatiMed - Vigorbuddy
    Ma. Corazon C. Consunji, MD, Makati Medical Center President & CEO (second from the left), signs the contract with UC Davis Comprehensive Cancer Center representatives.

    As Makati Medical Center celebrates its 50th Anniversary this year, the premiere hospital continues to drive advancement in medical care in the country by forging a partnership with one of the leading cancer centers in the United States.

    MakatiMed has partnered with UC Davis Comprehensive Cancer Center (UCDCCC) in a bid to boost cancer care in the Philippines. The agreement with the University of California, Davis-affiliated medical center includes the development of an international Cancer Care Network, a cancer registry in MakatiMed, training programs for cancer care, a second opinion program, and on-site clinical rotation from various subspecialties in oncology.

    Inpatient and outpatient procedures will be evaluated to enhance clinical workflows. The two hospitals will also share telemedicine programs and potentially collaborate in clinical trials, research studies, seminars, and multi-disciplinary teleconferences.

    UCDCCC, which was designated as a comprehensive cancer center by the US National Cancer Institute, offers the most advanced methods for the diagnosis, prevention, and treatment of cancers and blood disorders.

    “We want to introduce a collaborative approach in cancer care to offer the ideal treatments to our patients,” says Maria Corazon C. Consunji, MD, MakatiMed President and CEO. “This partnership will help MakatiMed achieve the best patient outcomes by embracing the advancements in oncology.”

    Dr. Consunji inked the contract with Primo N. Lara, Jr., MD, UCDCCC Director. Also present in the contract signing were UCDCCC’s Gina Dayton, Chief Administrative Officer and Associate Director for Administration, and Kristin Jones, Director for Oncology Services.

    For more information, please contact MakatiMed On-Call at +632.8888 999, email, or visit